Electra Therapeutics Sets Terms for $347M Nasdaq IPO
Question
Electra Therapeutics Sets Terms for $347M Nasdaq IPO
Direct answer
Electra Therapeutics established pricing terms for its Nasdaq initial public offering, planning to issue 21.7 million shares in a range of $14.00 to $16.00 per share under ticker ETRA. The deal would raise up to $347 million at the top end. Capital raised is allocated toward clinical progression of ipsoprubart through the SURPASS registration trial, targeting secondary haemophagocytic lymphohistiocytosis, providing a key benchmark for primary biopharma issuance sentiment. — bullish pressure on JEF.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-20
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Electra Therapeutics Sets Terms for $347M Nasdaq IPO”, revision 1, evidence through 2026-09-20. https://marketontology.com/catalysts/2026-09-20/electra-therapeutics-sets-terms-for-347m-nasdaq-ipo-dee55e
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| JEF | ▲Bull | 1–4 weeks | Policy Shift | 69 |
Electra Therapeutics Sets Terms for $347M Nasdaq IPO
Electra Therapeutics established pricing terms for its Nasdaq initial public offering, planning to issue 21.7 million shares in a range of $14.00 to $16.00 per share under ticker ETRA. The deal would raise up to $347 million at the top end. Capital raised is allocated toward clinical progression of ipsoprubart through the SURPASS registration trial, targeting secondary haemophagocytic lymphohistiocytosis, providing a key benchmark for primary biopharma issuance sentiment. — bullish pressure on JEF.
Electra Therapeutics established pricing terms for its Nasdaq initial public offering, planning to issue 21.7 million shares in a range of $14.00 to $16.00 per share under ticker ETRA. The deal would raise up to $347 million at the top end. Capital raised is allocated toward clinical progression of ipsoprubart through the SURPASS registration trial, targeting secondary haemophagocytic lymphohistiocytosis, providing a key benchmark for primary biopharma issuance sentiment.
- SummaryElectra Therapeutics established pricing terms for its Nasdaq initial public offering, planning to issue 21.7 million shares in a range of $14.00 to $16.00 per share under ticker ETRA. The deal would raise up to $347 million at the top end. Capital raised is allocated toward clinical progression of ipsoprubart through the SURPASS registration trial, targeting secondary haemophagocytic lymphohistiocytosis, providing a key benchmark for primary biopharma issuance sentiment.
- JEFDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- JEF closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- JEF price vs. pre-event level
- JEF volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-09-20Electra Therapeutics Sets Terms for $347M Nasdaq IPOETRA JEF
- 2026-09-20Electra Therapeutics Sets Nasdaq IPO Terms to Raise Up to $347MJEF
- 2026-09-20Electra Therapeutics Sets Nasdaq IPO Terms to Raise Up to $347METRA JEF
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.